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Amyloid β (Aβ) accumulation is considered the main culprit in the pathogenesis of
Alzheimer’s disease (AD). Recent studies suggest that decreasing Aβ production at very
early stages of AD could be a promising strategy to slow down disease progression.
Serotonin 5-HT4 receptor activation stimulates α-cleavage of the amyloid precursor protein
(APP), leading to the release of the soluble and neurotrophic sAPPα fragment and thus
precluding Aβ formation. Using the 5XFAD mouse model of AD that shows accelerated
Aβ deposition, we investigated the effect of chronic treatments (treatment onset at
different ages and different durations) with the 5-HT4 receptor agonist RS 67333 during
the asymptomatic phase of the disease. Chronic administration of RS 67333 decreased
concomitantly the number of amyloid plaques and the level of Aβ species. Reduction
of Aβ levels was accompanied by a striking decrease in hippocampal astrogliosis and
microgliosis. RS 67333 also transiently increased sAPPα concentration in the cerebrospinal
ﬂuid and brain. Moreover, a speciﬁc 5-HT4 receptor antagonist (RS 39604) prevented
the RS 67333-mediated reduction of the amyloid pathology. Finally, the novel object
recognition test deﬁcits of 5XFADmicewere reversed by chronic treatment with RS 67333.
Collectively, these results strongly highlight this 5-HT4 receptor agonist as a promising
disease modifying-agent for AD.
Keywords: alpha-secretase, sAPP alpha, serotonin, amyloid plaques, preventive pharmacotherapy, G protein-
coupled receptor
INTRODUCTION
Alzheimer’s disease (AD) is currently recognized as one of the
most socially devastating neurodegenerative disorders (Ferri et al.,
2005). AD pathogenesis is complex and relates to the dysfunction
of multiple systems. Current treatments to promote acetylcholine
(ACh) transmission or to inhibit NMDA receptors produce only
symptomatic beneﬁts (Melnikova, 2007), underscoring the urgent
need to ﬁnd disease-modifying treatments.
Alzheimer’s disease neuropathological hallmarks include extra-
cellular deposits of amyloid β (Aβ) peptides (amyloid plaques)
and intracellular aggregates of hyper-phosphorylated Tau pro-
tein (neuroﬁbrillary tangles; Glenner and Wong, 1984; Kang et al.,
1987; Alzheimer et al., 1995). According to the amyloid cascade
hypothesis, Aβ peptides and in particular the oligomeric forms
are critical determinants of synaptic loss and cognitive deﬁcits
in AD (Hardy and Selkoe, 2002). In line with this theory, recent
results from Phase III clinical trials indicate that Solanezumab, an
anti-Aβmonoclonal antibody, can bring some cognitive beneﬁt to
patients with mild AD-related dementia (Aisen et al., 2013), while
late interventions were unsuccessful (Sperling et al., 2013). Focus-
ing on prevention, three new studies are enrolling candidates to
test anti-amyloid agents in asymptomatic AD patients (Mullard,
2012).
Aβ peptides are generated by sequential β- and γ-secretase
cleavage of the amyloid precursor protein (APP). Conversely, non-
amyloidogenic cleavage by α-secretase within the Aβ sequence
releases the neuroprotective soluble APP (sAPPα) fragment and
precludesAβ generation (Fahrenholz,2007). Previous reports have
shown that G protein-coupled receptors can enhance sAPPα pro-
duction by stimulating α-secretase activities. They include several
neurotransmitter receptors such as muscarinic M1–M3 acetyl-
choline receptors [initially demonstrated by Nitsch et al. (1992)],
mGlu2 metabotropic glutamate receptor, serotonin 2A (5-HT2A),
and2C (5-HT2C) receptors [reviewed inThathiah andDeStrooper
(2011)]. Activation of serotonin type 4 (5-HT4) receptors also
stimulates APP α-cleavage and constitutes an increasingly attrac-
tive therapeutic strategy against amyloid toxicity. We and others
have demonstrated that 5-HT4 receptor agonists promote the
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release of sAPPα in vitro and in vivo (Maillet et al., 2003; Cochet
et al., 2013), an effect that reﬂects the reduction in Aβ production
anddeposition (Cho andHu,2007; Hashimoto et al., 2012; Tesseur
et al.,2013). 5-HT4 receptor agonists also improvememorydeﬁcits
by increasing ACh neurotransmission (Consolo et al., 1994; Bock-
aert et al., 2011; Johnson et al., 2012). Moreover, Donepezil, an
acetylcholinesterase inhibitor, acts in synergy with 5-HT4 receptor
agonists to enhance sAPPα release and to exert promnesic effects
in behavioral tests in mice (Cachard-Chastel et al., 2008; Freret
et al., 2012). In addition, a post-mortem study showed a reduc-
tion of 5-HT4 receptor density in brains of AD patients (Reynolds
et al., 1995). Thus, 5-HT4 receptor activation may have beneﬁcial
effects in AD both by reducing Aβ production and by improving
memory performances.
Here, we tested the hypothesis that chronic administration
of the 5-HT4 receptor agonist RS 67333 may shift APP cleavage
toward sAPPα production, thus inhibiting amyloid formation and
improving the cognitive performance in 5XFAD mice, a model
of AD (Oakley et al., 2006). Our results suggest that this 5-HT4
receptor agonist efﬁciently slows down amyloidogenesis during
the prodromal-like stage of the pathology andhighlight the impor-
tance of early intervention to enhance the chances of signiﬁcant
therapeutic effects.
MATERIALS AND METHODS
MICE
Animal experiments were carried out in accordance with the
Directive by theCouncil of the EuropeanCommunities of Novem-
ber 24, 1986 (86/609/EEC). All efforts were made to minimize
animal suffering and to reduce the number of mice used.Wild type
(WT) male C57BL/6 mice (8-week-old) were obtained from Jan-
vier (LeGenest-Saint-Isle, France). The generation of 5XFADmice
was described previously (Oakley et al., 2006). These transgenic
mice overexpress both human APP (695) harboring the Swedish
(K670N, M671L), Florida (I716V) and London (V717I) familial
AD (FAD) mutations and human Presenilin 1 (PS1) harboring the
two FAD mutations M146L and L286V. Expression of both trans-
genes is regulated by neuronal-speciﬁc elements of themouseThy1
promoter. The 5XFAD strain (B6/SJL genetic background) was
maintained by crossing hemizygous transgenic mice with B6/SJL
F1 breeders (Janvier). 5XFAD heterozygous transgenic mice were
used for the experiments and WT littermates as controls. All ani-
mals were genotyped by PCR using tail genomic DNA. Transgenic
and WT mice were bred in our animal facility, had access to food
and water ad libitum and were housed under a 12 h light-dark
cycle at 22–24◦C. Female 5XFAD mice were used in this study. For
each experiment, the age of mice is indicated in months (with a
2-week range).
DRUGS
The following compounds were used: RS 67333 (1-(4-amino-
5-chloro-2-methoxy-phenyl)-3-(1-butyl-4-piperidinyl)-1-propa-
none) and RS 39604 (1-[4-amino-5-chloro-2-(3,5-dimethoxy-
benzyl-oxy)phenyl]-3-[1-[2-[(methylsulfonyl)amino]ethyl]]-4-
piperidinyl]]-1-propanone hydrochloride). All drugs were
purchased from Tocris Bioscience (R&D Systems Europe, Lille,
France).
ANIMAL TREATMENTS
To induce acute 5-HT4 receptor activation in non-pathological
conditions, four different groups of WT C57BL/6 mice
(n = 6/group) received one intraperitoneal (i.p.) injection of vehi-
cle (0.9% w/v NaCl; 0.2% dimethyl sulfoxide in water), RS 67333
(selective 5-HT4 receptor partial agonist), RS 39604 (a 5-HT4
receptor antagonist), or both drugs (the antagonist was adminis-
tered 15 min before the agonist; 1 mg/kg each drug). Animals were
sacriﬁced 30 min after the injection, heads were quickly frozen
in liquid nitrogen, skulls opened on ice, and frontal cortex and
hippocampus dissected and stored at −80◦C for further analysis.
5XFAD mice and WT littermates received chronic treatments
with drugs or vehicle according to three different protocols. In
each experiment, drugs or vehicle solution were administered i.p.
twice a week (1 mg/kg). In “Protocol 1,”mice (n = 5) were treated
with RS 67333 from 1 to 4 months of age. In “Protocol 2,” mice
(n = 6) were treated for 2 months, from 2 to 4 months of age.
In “Protocol 3,” RS 67333 was administered for 1 month, from 2
to 3 months of age (n = 8). In addition, to antagonize RS 67333
effects, four different groups of mice (n = 4 each) received vehicle,
RS 67333, RS 39604, or both drugs (the antagonist was adminis-
tered 15 min before the agonist) according to protocol 2. At the
end of each protocol, mice were anesthetized with a mixture of
100 mg/kg ketamine and 10 mg/kg xylazine in saline solution and
perfused transcardially with PBS. Brains were quickly isolated on
ice, the olfactory bulbs and cerebellum removed and the two hemi-
spheres divided. One hemisphere was frozen on dry ice and stored
at −80◦C for biochemical analysis, while the other was post-ﬁxed
in 4% PFA for immunohistochemistry (IHC). WT mice, which
do not develop plaques, were used to investigate the possible toxic
effects of the drugs.
DETERMINATION OF sAPP PRODUCTION IN TRANSFECTED CELLS
COS-7 cells were grown in Dulbecco’s modiﬁed Eagle medium
(DMEM) supplemented with 10% dialyzed fetal calf serum
(dFCS) and antibiotics. Cells were transfected with plasmids
encoding HA-tagged 5-HT4 receptor and secreted placental alka-
line phosphatase (SEAP)-tagged mouse APP695, as previously
described (Cochet et al., 2013), and then seeded in 24-well
plates (250,000 cells/well). Twenty-four hours after transfec-
tion, cells were incubated with the appropriate drug concentra-
tion for 30 min, then culture supernatants were collected and
SEAP activity measured by adding the chromogenic substrate
p-Nitrophenyl phosphate disodium hexahydrate (Sigma-Aldrich,
Saint-Quentin Fallavier, France) according to the manufacturer’s
instructions. The reaction readout was performed at 405 nm
using an Inﬁnite 2000 luminescence counter (Tecan, Männedorf,
Switzerland). This technique measures all secreted soluble
forms of APP and does not discriminate between sAPPα and
sAPPβ.
CEREBROSPINAL FLUID COLLECTION
Mice were anesthetized and mounted onto a stereotaxic instru-
ment. The neck skin was cut and subcutaneous tissue and muscles
separated with the help of micro-retractors (Fine Science Tools,
Heidelberg, Germany). Mice were then laid down so that the head
formed an angle of about 135◦ with the body (Liu andDuff, 2008).
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A capillary tube (Borosilicate glass, B100-75-10, Sutter Instru-
ments, Novato, CA,USA) was used to punch the dura mater of the
cisterna magna. Cerebrospinal ﬂuid (CSF) was collected by cap-
illary action and transferred to 0.5 mL microtubes, immediately
frozen on dry ice and stored at −80◦C until use. Once thawed,
samples were heated at 60◦C for 5 min as described in Bourdin
et al. (2008) and analyzed without further freezing-thawing cycles.
BRAIN EXTRACT PREPARATION
Brain hemispheres, frontal cortex and hippocampus of 5XFAD
mice and controls were thawed, weighed, and homogenized in
four volumes of tris-saline (50 mM Tris-HCl pH = 7.4, 150 mM
NaCl) with a protease inhibitor cocktail (Roche Applied Science,
Meylan, France). The resulting homogenates were centrifuged at
540,000 × g for 20 min and supernatants (the “soluble fraction”)
collected and aliquoted for storage at −80◦C. Pellets were resus-
pended by brief sonication in 10 volumes of 6 M guanidine HCl in
50 mM Tris-HCl, pH = 7.6 and centrifuged again at 265,000 × g
for 20 min. Supernatants (the “insoluble fraction”) were aliquoted
and stored at −80◦C (Morishima-Kawashima et al., 2000).
QUANTIFICATION OF Aβ40, Aβ42, and sAPPα
ELISA kits from IBL International (Hamburg, Germany) for the
dosage of Aβ40 [human amyloid β (1–40) assay kit, #27713], Aβ42
[human amyloid β (1–42) assay kit, #27719] or sAPPα (mouse/rat
sAPPα assay kit, #27415; human sAPPα assay kit, #27734) were
used according to the manufacturer’s instructions. Reactions were
read at 620 and 450 nm using an Inﬁnite 2000 luminescence
counter. The obtained values were normalized to the protein con-
centration of each sample, measured using a BCA protein assay
(Sigma-Aldrich). The sAPPα ELISA kits enable the precise and
selective quantiﬁcation of sAPPα versus sAPPβ.
IMMUNOHISTOCHEMISTRY
Thirty-micrometer-thick sections were cut using a vibratome
(Microm HM 650 V, Thermo Scientiﬁc, Saint Herblain, France)
and stored in cryoprotectantmediumat−20◦C. For the labeling of
amyloid plaques, free-ﬂoating tissue sections of frontal cortex, hip-
pocampus, and entorhinal cortex (coordinates from the bregma:
frontal cortex = 1.98 mm, hippocampus = −1.94 mm, entorhinal
cortex = −3.08 mm) were extensively washed in PBS and then
incubated in blocking solution (PBS; 3% BSA; 0.1% Triton X-
100) for 1 h. Sections were stained with Hoechst dye (1:1000, Life
Technologies, Saint Aubin, France) for 15 min to detect cell nuclei
and then with freshly prepared thioﬂavin T solution (#T3516-
5G, Sigma-Aldrich; ﬁnal concentration: 0.01 mg/ml in blocking
buffer) for 15 min. After washing in 70% ethanol for 5 min, sam-
ples were mounted on poly-lysine slides with coverslips. For GFAP
(glial ﬁbrillary acidic protein) or IBA1 (ionized calcium-binding
adapter molecule 1) staining, free-ﬂoating brain sections were
blocked as before and incubated with polyclonal rabbit anti-GFAP
(1:1000, Z0334, Dako, Les Ullis, France) or anti-IBA1 antibodies
(1:3000, 019-19741, Wako Chemicals GmbH, Neuss, Germany)
at 4◦C overnight. After thioﬂavin T staining and washing with
70% ethanol, the secondary Alexaﬂuor 594 goat anti-rabbit anti-
body (1:1000, A11012, Life Technologies) was added for 2 h. PBS
washes and mounting were performed as described before.
IMAGE ACQUISITION AND ANALYSIS
Images were acquired with an AxioImager Z1 microscope (Carl
Zeiss S.A.S.,Marly le Roi, France). Analysis of thioﬂavin T staining
was performed blindly and data are presented as themean number
of particles per mm2 in two tissue sections from the same brain
area/animal (Image J software). GFAP and IBA1 expression were
quantiﬁed in hippocampus (dentate gyrus) using the samemethod
and results were expressed as area fractions. For representative
images of thioﬂavin T and GFAP staining, mosaic sequential scans
with a 10× objective were taken. Detailed images of plaques were
captured with a 40× objective and selected Z-stacks were pooled
together.
NOVEL OBJECT RECOGNITION TEST
The cognitive performance of mice was tested using the novel
object recognition (NOR) test (Bevins and Besheer, 2006). Ani-
mals were extensively handled during drug treatment prior to the
test onset. Each day, mice were allowed to familiarize with the
test room for at least 1 h prior to the test. Testing was carried out
in a Plexiglas box (width: 35 cm, length: 20 cm, height: 20 cm)
placed in a dimly lit room. On day 1 and 2, each mouse was habit-
uated to the empty box for 10 min/day. On day 3, two objects
(constructed out of plastic toys) were positioned in the cage, 5 cm
away from the opposing walls. During the training session, each
animal was placed between the two objects, facing the wall and
then was allowed to explore the objects for 5 min. Mice were
then returned to their home cage and 1 h later went through a
5 min test session in which one of the two (familiar) objects was
replaced by a new one (novel). The whole experiment was video-
recorded and object exploration (time spent by the mouse nose
in contact with the object or by snifﬁng it at a distance ≤ 1 cm)
was blindly measured. Two parameters were considered: (1) the
exploration time (s) spent by the animal interacting with the two
familiar objects during the training session and (2) the exploration
time spent by the animal interacting with the novel object relative
to the total exploration time {[novel/(familiar + novel)] × 100}
during the test. A discrimination index was also calculated
{[novel − familiar]/[familiar + novel]}. Mice that failed to
explore either of the two objects or explored both objects for
less than 10 s during the training session were excluded from
the data analysis (two WT and two 5XFAD mice from a total of
28 mice).
STATISTICAL ANALYSIS
All values are expressed as the mean ± SEM. Signiﬁcant effects
of treatments were determined by ANOVA analysis followed by
Bonferroni’s or Tukey’s post hoc tests in the case of multiple com-
parison groups. In all other cases, the unpaired Student’s t test was
used. For all statistical tests, p < 0.05 was considered signiﬁcant.
Analysis was performed with GraphPad Prism 6.0a (GraphPad
Software, La Jolla, CA, USA).
RESULTS
5-HT4 RECEPTOR AGONISTS INDUCE sAPPα RELEASE IN VITRO AND
IN VIVO
To study sAPPα release upon acute 5-HT4 receptor activation in
non-pathological conditions, COS-7 cells that transiently express
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5-HT4 receptors and SEAP-tagged APP were stimulated with
increasing concentrations of the highly selective and widely char-
acterized 5-HT4 receptor agonist RS 67333 (Eglen et al., 1995;
Marchetti et al., 2000; Lamirault and Simon, 2001; Kemp and
Manahan-Vaughan, 2004) or with the natural agonist serotonin
(5-HT) for 30 min. Quantiﬁcation of sAPP in culture super-
natants by detection of alkaline phosphatase activity, as previously
described (Cochet et al., 2013), showed that both treatments
increased sAPP release and that 5-HT had the most prominent
effect (Emax = 34 ± 5% of 5-HT maximal release for RS 67333;
Figure 1A). Then, the release of sAPPα was investigated in vivo
in WT C57BL/6 mice after a single administration of RS 67333
(1 mg/kg, i.p.), as previously done for the two 5-HT4 receptor
agonists prucalopride and ML 103022 (Cachard-Chastel et al.,
2007). Thirty minutes after the injection, mice were sacriﬁced
and sAPPα concentration was measured in brain extracts from
the frontal cortex and hippocampus, two regions that express
5-HT4 receptors. Upon 5-HT4 receptor activation, sAPPα level
increased 2.33-fold (hippocampus) and 1.73-fold (frontal cor-
tex) relative to control values (Figure 1B). RS 67333-mediated
sAPPα release in both brain regions was prevented when the spe-
ciﬁc 5-HT4 receptor antagonist RS 39604 (Hegde et al., 1995)
was injected (1 mg/kg, i.p.) before RS 67333. On its own,
RS 39604 did not have any signiﬁcant effect (Figure 1B). Finally,
acute 5-HT4 receptor activation by RS 67333 (one i.p. injec-
tion, 1 mg/kg) increased signiﬁcantly sAPPα release also in the
FIGURE 1 |The RS 67333 5-HT4 receptor agonist induces sAPPα release
in vitro and in vivo. (A) COS-7 cells that transiently express 5-HT4 receptors
and SEAP-APP were stimulated with increasing concentrations of serotonin
or RS 67333 for 30 min and then sAPP release in culture supernatants was
measured by quantiﬁcation of alkaline phosphatase activity. Data are the
mean ± SEM of values obtained in a typical experiment performed in
triplicate. Two other experiments performed on different sets of cultured cells
yielded similar results. (B) sAPPα levels in hippocampus and frontal cortex
extracts of C57BL/6 mice were quantiﬁed 30 min after one i.p. injection of
RS 67333 (1 mg/kg) and/or of the 5-HT4 receptor antagonist RS 39604
(1 mg/kg, 15 min before RS 67333). sAPPα values are expressed in nanogram
per milligram total proteins (n = 6/group). (C,D) Kinetics analysis of sAPPα
release (C) and Aβ42 concentration (D) in CSF samples from 5XFAD mice
after acute RS 67333 administration (1 mg/kg, i.p., n = 5/group). Insets show
sAPPα (C) and Aβ42 (D) quantiﬁcation in hippocampal brain extracts at the
30 min endpoint. Data are the mean ± SEM. ∗p < 0.05, ∗∗p < 0.01 compared
with vehicle (unpaired Student’s t test and two-way ANOVA followed by
Bonferroni’s test).
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5XFAD transgenic mouse model of AD). Speciﬁcally, sAPPα con-
centration in CSF from treated 5XFAD mice reached a peak
90 min post-injection [(sAPPα) = 38.6 ± 10.9 for vehicle- and
73.9 ± 6.3 ng/ml for RS 67333-treated mice; n = 5/group] and
returned to basal levels 4 h after drug delivery (Figure 1C). sAPPα
level was also signiﬁcantly higher (1.51-fold relative to control
values) in the hippocampus of RS 67333-treated 5XFAD mice in
comparison to controls (Figure 1C inset, 30 min post-injection).
Conversely, Aβ42 concentration in CSF and hippocampus of
RS 67333-treated mice was not signiﬁcantly different compared to
controls (Figure 1D), indicating that acute 5-HT4 receptor stimu-
lation increases sAPPα release in hippocampus and CSF, without
affecting Aβ levels in CSF during the 4 h following RS 67333
administration.
EARLY CHRONIC ADMINISTRATION OF RS 67333 REDUCES THE
AMYLOID PLAQUE LOAD IN 5XFAD MICE
Amyloid plaques can be already observed in the brain of 2-
month-old 5XFAD mice and altered cognitive performances can
be detected at 4 months of age (Oakley et al., 2006; Girard et al.,
2013). Relative to AD progression in humans, we speculated that
4-month-old 5XFAD mice were entering the “clinical stage of AD”
after a prodromal phase and a latent phase of variable duration
(Figure 2A). To test whether chronic treatment with the 5-HT4
receptor agonist RS 67333 could slow down amyloid plaque depo-
sition, we designed three treatment protocols (protocols 1–3) that
differed in terms of age at the onset of treatment and duration of
treatment, but not in the amount and frequency of administra-
tion (1 mg/ kg, i.p., twice a week, in all three; Figure 2A). Controls
were 5XFAD mice treated with vehicle. Frontal cortex, hippocam-
pus, and entorhinal cortex were analyzed as representative areas of
5XFAD mouse brain (frontal, median, and caudal sections) and of
human brain regions that are affected early by AD and are highly
enriched in amyloid deposits (Braak and Braak, 1991; Rowe and
Villemagne, 2013).
RS 67333 treatment (protocols 1 and 2) strongly decreased the
number of amyloid plaques compared to vehicle. The most signif-
icant effects were observed with protocol 1 (3 month-treatment,
from 1 to 4 months of age, Figure 2B), with a drastic reduc-
tion of amyloid plaque density (Aβ load) in all the analyzed brain
areas (Figure 2C; reduction of 37 ± 10% in the frontal cortex,
of 48 ± 8% in the hippocampus and of 55 ± 4% in the entorhi-
nal cortex, relative to controls treated with vehicle). In protocol 2
(delayed onset of the treatment, Figure 2A), a signiﬁcant reduc-
tion of the plaque number was still observed in the frontal and
entorhinal cortices (23 ± 8 and 35 ± 5%, respectively, relative to
control), but the small decrease in the hippocampuswas not signif-
icant (Figure 2D). Further shortening of the treatment (1 month,
protocol 3, Figure 2A), only resulted in a non-signiﬁcant trend
toward a decrease of the plaque number (Figure 2E). This suggests
that both treatment onset at early age and treatment duration are
crucial to obtain robust therapeutic effects.
CHRONIC ADMINISTRATION OF RS 67333 REDUCES Aβ40 and Aβ42
LEVELS IN 5XFAD MICE
Consistent with the reduced amyloid plaque load, quantiﬁcation
by ELISA showed a clear reduction of both Aβ40 and Aβ42 in the
insoluble fraction of brain samples from 5XFAD mice treated with
RS 67333 following protocol 1 (59 ± 11 and 61 ± 8% reduction
of Aβ40 and Aβ42, respectively, compared to controls; Figure 3A).
Conversely, Aβ40 andAβ42 decrease in the soluble fraction was not
signiﬁcant (Figure 3B). In the group treated following protocol
2, only Aβ42 levels were signiﬁcantly reduced in the insoluble and
soluble factions (33 ± 6 and 53 ± 15% reduction, respectively,
compared to controls; Figures 3C,D). One-month treatment with
RS 67333 (protocol 3) was not sufﬁcient to affect Aβ40 and Aβ42
accumulation in brains of 5XFAD mice (Figures 3E,F). Collec-
tively, these ﬁndings suggest that RS 67333 treatmentmight impact
total brain Aβ content.
RS 67333-INDUCED REDUCTION OF THE AMYLOID PATHOLOGY IS
MEDIATED BY 5-HT4 RECEPTOR ACTIVATION
To demonstrate the involvement of 5-HT4 receptors in the in
vivo effect of RS 67333, we examined whether RS 39604, a spe-
ciﬁc 5-HT4 receptor antagonist inhibits the protective effect of
the agonist in one of the protocols used in our study (protocol
2). Pre-treatment with RS 39604 (administered 15 min before
each RS 67333 injection) of a group of 5XFAD mice treated for
2months prevented theRS 67333-induced reduction inAβ42 levels
(Figure 4A) and the decrease in plaque formation in the entorhi-
nal (Figures 4B,C) and frontal cortices (Figure 4C). The 5-HT4
receptor antagonist had no effect on the amyloid burden when
administered alone for 2 months (Figures 4A–C). Collectively,
these data demonstrate that 5-HT4 receptor activation during the
prodromal phase of disease reduces Aβ accumulation and amyloid
plaque load in 5XFAD mice.
CHRONIC ADMINISTRATION OF RS 67333 REDUCES BRAIN TISSUE
INFLAMMATION IN 5XFAD MICE
Increasing evidence indicates that plaque deposition induces
astrogliosis and microgliosis in the brain of patients with AD.
Over the years, these chronic inﬂammation processes are likely
to contribute to AD progression (Akiyama et al., 2000; Wyss-
Coray and Rogers, 2012). We thus asked whether the anti-
amyloidogenic effects induced by RS 67333 could also lead to
reduction of brain inﬂammation in 5XFAD mice. Immunohis-
tochemical assessment of astroglial (anti-GFAP antibody) and
microglial (anti-IBA1 antibody) activation showed that RS 67333
chronic treatment (protocol 1) strikingly reduced both astrogliosis
(49 ± 9% decrease of GFAP staining in hippocampal brain slices
of treated animals in comparison to controls that received vehi-
cle; Figures 5A–C) and microgliosis (57 ± 9% reduction of IBA1
staining in treated animals compared to controls; Figures 5D,E).
In protocol 2, a slight but non-signiﬁcant reduction of astroglial
staining was seen in RS 67333-treated 5XFAD mice (data not
shown).
CHRONIC ADMINISTRATION OF RS 67333 REVERSES COGNITIVE
DEFICITS IN 5XFAD MICE
As acute stimulation of 5-HT4 receptors exerts pro-cognitive
effects on learning and memory (Letty et al., 1997; Marchetti-
Gauthier et al., 1997; Freret et al., 2012), we then investi-
gated whether chronic stimulation with RS 67333 (protocol
2, Figure 2A) could also improve cognitive performances via
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FIGURE 2 | Early, chronic administration of RS 67333 reduces the
amyloid plaque load in 5XFAD mice. (A) Schematic model comparing the
progression of AD in humans and of the AD-like pathology in 5XFAD mice. Aβ
accumulation in 5XFAD mice starts at 2 months of age, which corresponds to
AD asymptomatic phase in humans. The ﬁrst memory and behavioral deﬁcits
in 5XFAD mice appear at about 4 months of age, which corresponds to the
prodromal phase preceding the time of diagnosis in humans (clinical AD),
prior to progressive accumulation of neuropathological alterations and
memory deﬁcits in 5XFAD mice. The time-course of the three different
treatment protocols (protocols 1–3) with the 5-HT4 receptor agonist RS 67333
(1 mg/kg, i.p., twice a week) is shown below the schematic of disease
progression. At the end of the treatment, the behavioral NOR test (only for
mice treated according to protocol 2), Aβ40 and Aβ42 measurements in brain
extracts, quantiﬁcation of amyloid plaques and glial reactivity in brain slices
were performed. (B) Representative images of thioﬂavin T staining of amyloid
plaques in the frontal cortex (a,d), hippocampus (b,e), and entorhinal cortex
(c,f) (B) from 5XFAD mice treated with RS 67333 (protocol 1) or vehicle alone.
Images are mosaics collected with an AxioImager Z1 microscope, 10X
objective (b–d). Quantiﬁcation of Aβ load (number of plaques/mm2) in frontal
cortex, hippocampus and entorhinal cortex following RS 67333 treatment
using protocol 1 (C), protocol 2 (D) or protocol 3 (E). Data are the
mean ± SEM, n ≤ 5/group. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared
with vehicle (unpaired Student’s t test). I-VI, cortical layers; Cx, cortex; cc;
corpus callosum; CA1 and 3, cornu ammonis areas 1 and 3, DG; dentate
gyrus; Th, thalamus; Hb, habenula; Prh, perirhinal cortex; DIEnt, dorsal
intermediate entorhinal ﬁeld; vSub, ventral subiculum.
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FIGURE 3 | Early chronic administration of RS 67333 reduces Aβ40 and
Aβ42 levels in 5XFAD mice. 5XFAD female (3 or 4 months at termination)
mice were treated chronically with 1 mg/kg RS 67333 twice a week according
to protocol 1 (A,B), protocol 2 (C,D) or protocol 3 (E,F). Total Aβ40 and
Aβ42species were quantiﬁed in the insoluble (A,C,E) and soluble (B,D,F) brain
fractions. Data are the mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001
compared with vehicle (unpaired Student’s t test). The mean levels (nanogram
per milligram total protein ± SEM, n = 5/group) in the three vehicle-treated
groups (protocol 1, 2, and 3, respectively) were: insoluble Aβ40: 483 ± 13,
346 ± 62, and 187 ± 31; insoluble Aβ42: 2006 ± 38; 2190 ± 265, and
1477 ± 322; soluble Aβ40: 7.62 ± 1.52, 3.97 ± 0.81, and 10.75 ± 0.87; soluble
Aβ42: 0.44 ± 0.07, 0.82 ± 0.02, and 2.48 ± 0.59.
preventive reduction of Aβ formation. These behavioral studies
were performed using protocol 2, which is the most relevant pro-
tocol for translation into a treatment of the human pathology
(drug delivery at the adult stage). 5XFAD mice and WT litter-
mates were thus treated for 2 months with RS 67333 or vehicle
and then their episodic-like memory was tested using the NOR
test that is classically employed in mouse models of AD (Bevins
and Besheer, 2006). Training sessions were started 3 days after
the end of treatment, thus acute effects of RS 67333 cannot
inﬂuence the test. Body weight and global health monitoring
throughout the treatment showed that chronic RS 67333 treat-
ment did not induce adverse effects in 5XFAD andWT littermates.
Impaired ability to discriminate between the familiar and novel
objects after 1 h retention interval was observed in 5XFAD mice
treated with vehicle compared to WT littermates (Figures 6A,B),
in agreement with the fact that 5XFAD mice start to show altered
cognitive functions at 4 months of age (Oakley et al., 2006; Jawhar
et al., 2012; Girard et al., 2013). Conversely, cognitive impair-
ment was completely prevented in RS 67333-treated 5XFAD mice
(Figures 6A,B). RS 67333 did not have a pro-cognitive effect
in WT littermates in these experimental conditions. Finally, the
total exploration time during the training session did not dif-
fer signiﬁcantly in the four groups (Figure 6C), indicating that
the recognition memory improvement in 5XFAD mice treated
with RS 67333 is not secondary to an increase of the exploratory
activity.
DISCUSSION
In this study, we show that early, chronic administration of the
5-HT4 receptor agonist RS 67333 reduces the amyloid burden and
inﬂammationmarkers (astrogliosis andmicrogliosis) andprevents
memory impairment in 5XFAD mice. We also demonstrate that
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FIGURE 4 | RS 67333-induced reduction of amyloid pathology is
prevented by pre-administration of the 5-HT4 receptor antagonist
RS 39604.Two-month-old 5XFAD females were treated with RS 67333
according to protocol 2 (1 mg/kg, twice a week, for 2 months) with or
without pre-administration (15 min before) of the 5-HT4 receptor antagonist
RS 39604. (A) Quantiﬁcation of Aβ42 load in the brain insoluble and soluble
fractions. The mean concentration (nanogram per milligram total
protein ± SEM, n = 4/group) of Aβ42in the soluble and insoluble fractions
from the vehicle-treated group was 0.77 ± 0.10 and 2079.0 ± 203.8,
respectively. (B). Representative images of thioﬂavin T staining in the
entorhinal cortex (mosaics, 10× objective). (C) Quantiﬁcation of plaque
number. Data are the mean ± SEM. ∗p < 0.05, ∗∗p < 0.01 compared with
vehicle (unpaired Student’s t test).
starting the treatment early (during the prodromal phase of the
neurodegenerative disease) and its duration are both crucial to
signiﬁcantly reduce the levels of Aβ species and plaque formation.
Amyloid precursor protein non-amyloidogenic processing and
sAPPα release upon agonist-mediated 5-HT4 receptor activation
is now well established in cell lines and primary neuronal cultures
(Maillet et al., 2003; Hashimoto et al., 2012; Cochet et al., 2013;
Tesseur et al., 2013). Moreover, both short and chronic (once
a day for 10 days) 5-HT4 stimulation with high RS 67333 dose
(3 mg/kg, i.p.) can reduce amyloidogenesis in 10- to 12-month-
old Tg2576 mice (another mouse model of AD) possibly through
matrix metalloproteinase-9 (MMP-9) up-regulation (Hashimoto
et al., 2012). Another recent study evaluated the effects of acute
and chronic treatment with a novel but not fully characterized 5-
HT4 agonist (SSP-002392) in APP/PS1 mice that express human
APP with the Swedish mutations and mutant human PS1 (Tesseur
et al., 2013). Despite no evidence for direct α-secretase stimula-
tion in the brain, the authors showed a reduction in soluble and
insoluble Aβ in the hippocampus accompanied by a decrease in
APP and BACE1 (β-secretase 1/beta-site APP cleaving enzyme 1)
expression and elevated astroglial and microglial responses. More-
over, reduction of the amyloid pathology upon chronic treatment
(37 days) was detected only in the brain of 4- to 5-month-old
but not of 12-month-old APP/PS1 mice, in which abundant Aβ
deposits were still present. This previous study is not directly
comparable to the current report for the two following reasons:
(1) higher and more frequent 5-HT4 agonist administration were
performed in the previous study; (2) themodel used (Tg2576) was
far less aggressive and easier to cure than the mouse model that
was used here (5XFAD). Therefore, our work brings new insights
into the 5-HT4 receptor-induced non-amyloidogenic cleavage of
APP and the potential of 5-HT4 agonists to slow down disease
progression.
TRANSIENT INCREASE OF sAPPα IN THE CSF OF 5XFAD MICE UPON RS
67333 5-HT4 AGONIST INJECTION
We observed a signiﬁcant increase of sAPPα release in both hip-
pocampus and frontal cortex of WT C57BL/6 mice after one
i.p. injection of the 5-HT4 receptor agonist RS 67333 at low
doses (1 mg/kg). This effect was reversed by a 5-HT4 receptor
antagonist. Moreover, we show for the ﬁrst time an increase
in sAPPα accumulation in the CSF of 5XFAD mice following
RS 67333 administration. Kinetic studies indicated that sAPPα
was only transiently increased in CSF, a ﬁnding that might explain
why sAPPα production is difﬁcult to detect in brain samples
(Cachard-Chastel et al., 2007; Tesseur et al., 2013). Therefore,
to accurately monitor sAPPα level variations in CSF, it might
be necessary to precisely identify the optimal sample collection
time, based on the drug administration route and bioavailabil-
ity. This transient sAPPα increase might also explain why we
could not detect any increase in sAPPα in the soluble frac-
tion of brain extracts after chronic treatments (not shown). The
extent of 5-HT4 receptor-mediated sAPPα release in CSF could
also constitute a biomarker to follow the capacity to induce
non-amyloidogenic APP cleavage in AD brains in which the 5-
HT4 receptor density is known to be reduced (Reynolds et al.,
1995).
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FIGURE 5 | Early chronic administration of RS 67333 reduces
astrogliosis and microgliosis in 5XFAD mice. One-month-old 5XFAD
females were treated according to protocol 1 (1 mg/kg RS 67333
twice a week for 3 months). Representative images of hippocampus
sections from controls (vehicle) and treated mice show GFAP [(A,B) in
red and pseudo-colored in white, respectively], IBA1 [(D) in red],
thioﬂavin T [(A,B,D) in green] and Hoechst staining [(A,D) in blue].
Images in A are mosaics, 10× objective; images in (B) are higher
magniﬁcations (40× objective) of distinct plaques indicated by white
arrowheads in (A). Quantiﬁcation of GFAP (C) and IBA1 (E) staining,
markers of astroglia and microglia, respectively. Data are presented as
the mean ± SEM. ∗p < 0.05 compared with vehicle (unpaired
Student’s t test). GFAP, glial ﬁbrillary acidic protein; IBA1, ionized
calcium-binding adapter molecule 1; Cx, cortex; cc, corpus callosum;
CA1 and 3, cornu ammonis areas 1 and 3; DG, dentate gyrus; GC,
granule cells; Hil, hilus.
REDUCTION OF Aβ SPECIES AND AMYLOID PLAQUES
The 5-HT4 receptor-inducedAPP α-cleavage should, de facto, pre-
clude Aβ formation. Although acute RS 67333 administration did
not induce any signiﬁcant change in the Aβ42CSF content within
a 4 h-period, we observed a decrease of Aβ40−42production and
Aβ deposits (plaques) in all brain regions after early, chronic treat-
mentwith RS 67333 (up to 3months). These data are in agreement
with previous in vitro results showing that RS 67333 inhibits in a
dose-dependent manner the generation of Aβ40−42 species in pri-
mary cortical cultures of Tg2576 mice over a 2-day accumulation
period (Cho and Hu, 2007).
Amyloid plaques seem to be the ﬁnal response of the organism
to the progressive increase in Aβ concentration (Gandy, 2011).
Interestingly, in RS 67333-treated mice, the reduction of insoluble
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FIGURE 6 | Chronic administration of RS 67333 prevents object
recognition memory loss in 5XFAD mice. Two-month-old 5XFAD females
(Tg) andWT littermates were treated with RS 67333 or vehicle according to
protocol 2 (1 mg/kg, twice a week for 2 months) and then recognition
memory was assessed with the novel object recognition (NOR) test.
Habituation sessions were started 3 days after the end of treatment and the
interval between training session and test was of 1 h. (A) RS 67333-treatment
reverses cognitive impairment as indicated by the higher percentage of time
devoted to the exploration of the novel object in comparison to mice treated
with vehicle. Data are the mean ± SEM (n = 6–7 mice/group). ∗p < 0.05,
∗∗p < 0.01 versus familiar object (two-way ANOVA followed by Bonferroni’s
test). (B)This ﬁnding was conﬁrmed also by calculating the discrimination
index [(novel − familiar)/(familiar + novel)]. Data are the mean ± SEM. Indices
different from zero: ∗p < 0.05, ∗∗p < 0.01 (unpaired Student’s t test).
§p < 0.05 versusTg-vehicle group (two-way ANOVA followed byTukey’s test).
(C)The total exploration time was not signiﬁcantly different among groups.
Aβ specieswasmore pronounced than that of soluble fractions and
correlated well with the number of amyloid deposits. According
to the amyloid hypothesis, when soluble Aβ level (especially Aβ42,
which is the species with the most propensity to aggregate) reaches
a critical concentration, aggregation might begin to occur, leading
to plaque formation. Therefore, the decrease in amyloid plaque
formation, following chronic 5-HT4 receptor activation, might
result from a shift of APP cleavage toward the non-amyloidogenic
pathway. The apparent discrepancy with the absence of change
in Aβ42 level following acute treatment with the 5-HT4 receptor
agonist might reﬂect the slower kinetic of Aβ production, which
requires two consecutive enzymatic cleavages. Further studies are
needed to precisely characterize the effects of 5-HT4 receptor ago-
nists on the release in CSF of other products of APP metabolism,
an issue that we could not address in the present study due to
insufﬁcient amount of material available. Collectively, our results
are consistent with a decrease in Aβ accumulation that conse-
quently diminish the number of amyloid plaques in diseased
brains and with a preventive action of chronic treatment with RS
67333.
REDUCTION IN ASTROGLIOSIS AND MICROGLIOSIS
We demonstrated a clear decrease in glial reactivity upon chronic
5-HT4 receptor activation, in contrast with recent results using
the 5-HT4 agonist SSP-002392 in APP/PS1 mice (Tesseur et al.,
2013). The explanation for such discrepancy in the effect of two
5-HT4 receptor agonists requires to be elucidated. The 5-HT4
receptor is coupled to GS protein, thus its activation by agonists
induces cAMP production, an event linked to anti-inﬂammatory
processes in the microglia (Kim et al., 2000). Moreover, 5-HT4
receptor agonists have been described to inhibit the interferon-γ-
mediated immune response in cultured astrocytes (Zeinstra et al.,
2006) and to have an anti-inﬂammatory role in the intestinal
smooth muscle layer (Tsuchida et al., 2011). Therefore, 5-HT4
receptor stimulation is more likely to reduce inﬂammation. In
addition, as amyloid deposits seem to induce inﬂammation in
diseased brains (Akiyama et al., 2000), reducing Aβ burden and
plaque number should concomitantly decrease inﬂammation. The
new agonist SSP-002392 used in the previous study may have
side effects that are non-related to its agonist action on 5-HT4
receptors, as suggested by Tesseur et al. (2013). Here, we antag-
onized the action of RS 67333 on plaque number and Aβ load
by co-administration of a speciﬁc 5-HT4 receptor antagonist,
RS 39604, that produced no effect when administered alone in
5XFAD mice. Both compounds have been reported to bind sigma
receptors expressed in various brain regions (Eglen et al., 1995;
Hegde et al., 1995), but no data are available on isolated σ1 recep-
tor, the only sigma receptor cloned to date. Although it is unlikely
that RS 67333 and RS 39604 act as an agonist and an antagonist at
sigma receptors, respectively, using other 5-HT4 antagonists with
different chemical structure, such as GR 113808 or GR 125487,
would deﬁnitely exclude sigma receptor involvement. Inﬂamma-
tion progression is linked to AD course and long-term treatment
with anti-inﬂammatory drugs reduces the risk to develop the dis-
ease. Reducing astrogliosis and microgliosis might thus have a
beneﬁcial outcome and contribute to slow down the pathology
(Wyss-Coray and Rogers, 2012).
EARLY INTERVENTION
In this study, we compared different protocols of chronic admin-
istration of RS 67333 to obtain the most efﬁcient preventive effect
in 5XFAD mice that were in the “prodromal stage” of disease
(i.e., before the appearance of cognitive decline; Figure 2A). We
observed the strongest effects with protocol 1, which combined
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very early treatment onset (1-month-old mice) and longest dura-
tion (3 months). In contrast, the 1-month treatment at a later
stage of disease was insufﬁcient to trigger signiﬁcant improve-
ment, consistent with the observation by Tesseur et al. (2013) who
reported that a 37-day treatment was ineffective in APP/PS1 mice.
5-HT4 receptors undergo rapid and sustained desensitization in
neurons (Ansanay et al., 1992) and, consequently, they could be
down-regulated upon prolonged agonist exposure. To limit this
risk, we used a partial 5-HT4 receptor agonist at moderate doses
(1 mg/kg) and only twice a week, not daily. Finally, our ﬁndings
demonstrate that a 2-month-long chronic treatment is already suf-
ﬁcient to prevent the appearance of cognitive deﬁcits in 5XFAD
mice. Collectively, our results clearly show that 5-HT4 agonists
given at an early stage of the disease (before the appearance of
cognitive decline) act preventively on Aβ formation and can pre-
serve memory performance in 5XFAD mice. The necessity of early
intervention regardingADmousemodels has also been established
for other therapeutic strategies such as γ-secretase inhibition (Das
et al., 2012).
In line with our results, it has been shown that enhancing sero-
tonin signaling by administration of selective serotonin reuptake
inhibitors (SSRI) is associated with lower Aβ levels and reduced
number of plaques in mice and humans (Cirrito et al., 2011).
Amyloid accumulation in the brain can precede AD symptoms by
10 years (Morris and Price, 2001) and even by more than 25 years
in genetic forms of AD (Bateman et al., 2012). Therefore, acting as
early as possible in the disease process seems to be crucial to slow
down the pathology evolution. Although further investigations are
needed to understand the complexity of 5-HT4 agonist actions,
our data strongly suggest that these compounds are promising
disease modifying-agents for AD.
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